ClinicalTrials.gg
TerminatedNCT02909140Updated Sep 10, 2019Results posted

Optimal Method for Mydriasis in Cataract Surgery

An interventional study of Topical phenylephrine 2.5% and Topical cyclopentolate 1% in Cataract, sponsored by Johns Hopkins University. Terminated at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-09-10.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Other

Why this study was terminated
insufficient patient recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.

Enrollment
307th of 322
3 · median 100
Started
2016
with 5 others
No phase
150 of 456
17 open now
Registered
225th of 456
by date

Among the 456 studies in Cataract with a site in United States, this one is the 307th largest by enrollment of the 322 interventional ones that give a count, is one of 6 that started in 2016, is one of 150 with no phase, and was the 225th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Cataract with a site in United States, or all of them as a file.
02

Study summary

Obtaining appropriate mydriasis prior to cataract surgery is an important variable in successful surgery. The current practice includes using topical anticholinergic and sympathomimetic agents in the preoperative area prior to cataract surgery, but the pupils are sometimes insufficiently dilated and can often need additional mydriasis with intracameral agents during cataract surgery. Pre-operative topical mydriatic drops take time to take effect, are mildly uncomfortable for the patient, and have a cost to the healthcare system. If intracameral mydriasis alone can achieve adequate pupil dilation, perhaps topical mydriatics would not be needed. The purpose of this study is to evaluate whether topical versus intracameral versus topical + intracameral mydriasis is the optimal way to dilate pupils during routine cataract surgery. The results of this study have implications for improving the efficiency and reducing time prior to cataract surgery. In addition, it has significant potential to reduce the cost associated with cataract surgery if preoperative drops can be eliminated.

Read the detailed description

Recent research has compared the use of intracameral and topical agents with the preoperative pupil size and cataract surgery success. Studies have compared topical mydriatics with intracameral lidocaine and found no significant difference in dilation. , Other studies have compared topical mydriatics with intracameral dilation that includes solutions with and without epinephrine in the irrigating solution and concluded that irrigating solutions without epinephrine can safely be used with intracameral mydriatics but epinephrine is useful when using topical mydriatics. There have also been studies comparing the success of longer acting drug inserts of mydriatic agents with the use of intracameral agents. In addition to these standard agents, different surgeons have used various formulations of topical and intracameral agents to perform mydriasis. As of yet, there is no formal, standardized method for mydriasis and no large prospective study comparing the outcomes of the various methods. Considerations such as cost and time spent on preoperative mydriatic agents in light of the amount of success seen with these agents calls into question the need for such agents. The investigators would like to study the amount of pupillary dilation seen with topical preoperative mydriatic agents compared to intracameral agents compared to the use of them both together.

This will be a prospective randomized controlled trial. Patients will be consented and enrolled at their pre-op visit. They will be randomized to topical drops alone, intracameral injection alone, or topical plus intracameral mydriasis. All patients will receive intracameral lidocaine, as this is used for its anesthetic effect but also has some mydriatic effect. The intervention will take place on the day of the operation. Patients will be followed until post-operative month #1.

Data will be gathered on 4 visits: pre-op clinic visit, day of operation, and post-operative day #1 and post-operative month #1. These are all standard visits for routine cataract surgery, and this study will not require the patient to make any extra visits. Enrollment will continue until the sample size is met.

Patients cannot be blinded to whether or not they receive topical mydriasis eyedrops, and no placebo drops are necessary because patients cannot voluntarily control their pupillary constriction, so no placebo effect would be expected. The surgeon cannot be blinded to whether or not the patient has received topical mydriasis eyedrops in the pre-op area because it will be evident based upon whether or not the patient's eye is dilated. Another researcher who was not present in the operating room will grade the photographs and measure the pupil size, and this researcher will be blinded to which intervention the patient received.

Currently, some surgeons use topical plus intracameral mydriasis for mydriasis during cataract surgery. It is hypothesized that intracameral mydriasis alone may be sufficient to adequately dilate the pupil for cataract surgery. Patients who are not adequately dilated at the time of pupil size measurement immediately before the capsulorrhexis step will subsequently receive additional pharmacologic mydriasis, visco-dilation, or iris expansion devices to dilate their pupil to a size that is adequate for their surgery. Therefore, no matter which group the patient is in, their pupil will be eventually dilated to a size that is adequate to proceed with surgery.

There is no placebo or non-treatment group, since all patients must be somehow dilated in order to undergo cataract surgery. The purpose of this study is to compare 3 methods of dilation.

The pupil size will be measured after the viscoelastic is injected and before the capsulorrhexis is performed. Treatment failure is defined as a pupil size that is clinically deemed too small to safely proceed with surgery (approximately less than 5 mm). At this point, a rescue intervention will be implemented with additional pharmacologic mydriasis, visco-dilation, or iris expansion devices, until the pupil is adequately dilated to proceed with surgery. These patients will still be included in the study, and their pupil size prior to the rescue intervention is still the primary outcome.

Participants can choose to stop participating in the study prior to receiving any of the mydriasis agents. Should they choose to withdraw from the study, they would end up receiving routine mydriasis with topical plus intracameral agents. The study ends on post-op month #1 for all individual patients. The study enrollment period will end when the sample size is met.

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients aged 40 or older who are undergoing routine cataract surgery under topical anesthesia with monitored anesthesia care at the Wilmer Eye Institute with Dr. Fasika Woreta and her senior resident proficient at cataract surgery.

Exclusion criteria

Exclusion Criteria:

  • Need for general anesthesia
  • Maximum pupillary dilation \<6.0mm at the pre-op clinic visit.
  • Prior intra-ocular surgery
  • Prior trauma
  • Any pre-existing iris abnormalities including pupillary deformity, posterior synechiae, peripheral anterior synechiae, zonular dehiscence
  • Pseudoexfoliation
  • Allergy to any of the mydriasis agents
  • Pregnancy or breastfeeding
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Topical Mydriasis

    Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.

    Drug: Topical phenylephrine 2.5% · Drug: Topical cyclopentolate 1% · Drug: Intracameral Lidocaine 1%

  • Experimental
    Intracameral Mydriasis

    Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.

    Drug: Intracameral Lidocaine 1% · Drug: Intracameral 0.2- 0.3ml of epinephrine 1:10,000

  • Experimental
    Topical + Intracameral mydriasis

    Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia. Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.

    Drug: Topical phenylephrine 2.5% · Drug: Topical cyclopentolate 1% · Drug: Intracameral Lidocaine 1% · Drug: Intracameral 0.2- 0.3ml of epinephrine 1:10,000

Interventions

06

What researchers measure

Primary outcomes

  1. Pupil Size Immediately Prior to Capsulorrhexis

    Pupil size immediately prior to the capsulorrhexis step of cataract surgery. This will be recorded by digital photography and measured by a researcher who is masked to the intervention.

    Time frame: Immediately prior to the capsulorrhexis step of cataract surgery

Secondary outcomes

  1. Pupil Size (mm) Immediately After Nuclear Disassembly

    Pupil size immediately after breaking up of cataractous lens

    Time frame: Immediately after nuclear disassembly step of cataract surgery

  2. Pupil Size Immediately Prior to Intraocular Lens (IOL) Insertion

    Pupil size after insertion of IOL lens

    Time frame: Immediately prior to IOL insertion step of cataract surgery

  3. Pupil Size Upon Completion of Surgery

    Time frame: intraoperative

  4. Pupil Size on Post-operative Day 1

    Time frame: Post-operative Day 1

  5. Percentage of Patients in Each Arm That Required Another Mydriatic Agent

    Time frame: intraoperative

  6. Cumulative Energy Dispersed for Each Arm

    The amount of energy needed to break up the cataractous lens

    Time frame: During cataract surgery

  7. Mean Time Taken to Perform Phacoemulsification in Each Arm

    Time frame: intraoperative

  8. Percentage of Patients With an Increase in the Blood Pressure or Heart Rate

    Time frame: Baseline

  9. Percentage of Patients With an Increase in the Blood Pressure or Heart Rate

    Time frame: intraoperative

  10. Mean Time Taken to Perform Phacoemulsification

    Time frame: During cataract surgery

  11. Percentage of Patients in Each Arm That Required Use of an Iris Expansion Device During the Procedure

    Time frame: intraoperative

07

Results

Posted Sep 10, 2019

Participant flow

Participant flow — Overall Study
MilestoneTopical MydriasisIntracameral MydriasisTopical + Intracameral Mydriasis
Started020
Completed020
Not completed000

Outcome measures

PrimaryPupil Size Immediately Prior to Capsulorrhexis

Pupil size immediately prior to the capsulorrhexis step of cataract surgery. This will be recorded by digital photography and measured by a researcher who is masked to the intervention.

Time frame:
Immediately prior to the capsulorrhexis step of cataract surgery
Reported as:
Number · mm
Pupil Size Immediately Prior to Capsulorrhexis
mmTopical MydriasisIntracameral MydriasisTopical + Intracameral Mydriasis
Pupil Size Immediately Prior to Capsulorrhexis—8—
SecondaryPupil Size (mm) Immediately After Nuclear Disassembly

Pupil size immediately after breaking up of cataractous lens

Time frame:
Immediately after nuclear disassembly step of cataract surgery
Reported as:
Number · mm
Pupil Size (mm) Immediately After Nuclear Disassembly
mmTopical MydriasisIntracameral MydriasisTopical + Intracameral Mydriasis
Pupil Size (mm) Immediately After Nuclear Disassembly—8—
SecondaryPupil Size Immediately Prior to Intraocular Lens (IOL) Insertion

Pupil size after insertion of IOL lens

Time frame:
Immediately prior to IOL insertion step of cataract surgery
Reported as:
Number · mm
Pupil Size Immediately Prior to Intraocular Lens (IOL) Insertion
mmTopical MydriasisIntracameral MydriasisTopical + Intracameral Mydriasis
Pupil Size Immediately Prior to Intraocular Lens (IOL) Insertion—8—
SecondaryPupil Size Upon Completion of Surgery
Time frame:
intraoperative
Reported as:
Number · mm
Pupil Size Upon Completion of Surgery
mmTopical MydriasisIntracameral MydriasisTopical + Intracameral Mydriasis
Pupil Size Upon Completion of Surgery—7—
SecondaryPupil Size on Post-operative Day 1
Time frame:
Post-operative Day 1

No measurements were reported for this outcome.

SecondaryPercentage of Patients in Each Arm That Required Another Mydriatic Agent
Time frame:
intraoperative
Reported as:
Number · percent of participants
Percentage of Patients in Each Arm That Required Another Mydriatic Agent
percent of participantsTopical MydriasisIntracameral MydriasisTopical + Intracameral Mydriasis
Percentage of Patients in Each Arm That Required Another Mydriatic Agent—0—
SecondaryCumulative Energy Dispersed for Each Arm

The amount of energy needed to break up the cataractous lens

Time frame:
During cataract surgery
Reported as:
Number · Percent-seconds
Cumulative Energy Dispersed for Each Arm
Percent-secondsTopical MydriasisIntracameral MydriasisTopical + Intracameral Mydriasis
Cumulative Energy Dispersed for Each Arm—6.6—
SecondaryMean Time Taken to Perform Phacoemulsification in Each Arm
Time frame:
intraoperative
Reported as:
Number · seconds
Mean Time Taken to Perform Phacoemulsification in Each Arm
secondsTopical MydriasisIntracameral MydriasisTopical + Intracameral Mydriasis
Mean Time Taken to Perform Phacoemulsification in Each Arm—76—
SecondaryPercentage of Patients With an Increase in the Blood Pressure or Heart Rate
Time frame:
Baseline

No measurements were reported for this outcome.

SecondaryPercentage of Patients With an Increase in the Blood Pressure or Heart Rate
Time frame:
intraoperative

No measurements were reported for this outcome.

SecondaryMean Time Taken to Perform Phacoemulsification
Time frame:
During cataract surgery
Reported as:
Number · seconds
Mean Time Taken to Perform Phacoemulsification
secondsTopical MydriasisIntracameral MydriasisTopical + Intracameral Mydriasis
Mean Time Taken to Perform Phacoemulsification—76—
SecondaryPercentage of Patients in Each Arm That Required Use of an Iris Expansion Device During the Procedure
Time frame:
intraoperative
Reported as:
Number · percent
Percentage of Patients in Each Arm That Required Use of an Iris Expansion Device During the Procedure
percentTopical MydriasisIntracameral MydriasisTopical + Intracameral Mydriasis
Percentage of Patients in Each Arm That Required Use of an Iris Expansion Device During the Procedure—50—

Adverse events

Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Topical Mydriasis———
Intracameral Mydriasis0/2 (0%)0/2 (0%)0/2 (0%)
Topical + Intracameral Mydriasis———

Baseline characteristics

Absent enrollment

Age, Categorical
Age, Categorical(Participants)Topical MydriasisIntracameral MydriasisTopical + Intracameral MydriasisTotal
<=18 years—0—0
Between 18 and 65 years—0—0
>=65 years—2—2
Sex: Female, Male
Sex: Female, Male(Participants)Topical MydriasisIntracameral MydriasisTopical + Intracameral MydriasisTotal
Female—1—1
Male—1—1
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Topical MydriasisIntracameral MydriasisTopical + Intracameral MydriasisTotal
Count of participants———0
Systolic blood pressure in preoperative area
Systolic blood pressure in preoperative area(mmHg)Topical MydriasisIntracameral MydriasisTopical + Intracameral MydriasisTotal
Mean—144 (140 to 148)—144 (140 to 148)
Heart rate in preoperative area
Heart rate in preoperative area(bpm)Topical MydriasisIntracameral MydriasisTopical + Intracameral MydriasisTotal
Mean—75.5 (62 to 89)—75.5 (62 to 89)
Systolic blood pressure on entry to OR
Systolic blood pressure on entry to OR(mmHg)Topical MydriasisIntracameral MydriasisTopical + Intracameral MydriasisTotal
Mean—172 (169 to 176)—172 (169 to 176)
Heart rate on entry to OR
Heart rate on entry to OR(bpm)Topical MydriasisIntracameral MydriasisTopical + Intracameral MydriasisTotal
Mean—80.5 (72 to 89)—80.5 (72 to 89)
08

Study locations

1 site
  • Wilmer Eye Institute, Johns Hopkins
    Baltimore, Maryland 21287, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Aug 2018, 23 months.

Results were first posted in Sep 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2016
First posted
Sep 21, 2016
StartActual
Sep 2016
Primary completionActual
Aug 15, 2018
CompletionActual
Aug 15, 2018
Results first posted
Sep 10, 2019
Last update
Sep 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02909140
Responsible party
Sponsor
First posted
Sep 21, 2016
Start date
Sep 2016
Primary completion
Aug 15, 2018
Completion
Aug 15, 2018
Results posted
Sep 10, 2019
Last update
Sep 10, 2019

Study contacts

Fasika Woreta, M.D., M.P.H
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Phenylephrine · Cyclopentolate

Start the discussion